FLT3 and acute myeloid leukemia: The staurosporine analog midostaurin, marketed as RydaptTM and TauitmoTM, is approved for the treatment of newly diagnosed acute myeloid leukemia cases that have mutations in the FMS-like tyrosine kinase 3 (FLT-3) tyrosine kinase.